Breast cancer deaths disproportionately affect individuals in low- and middle-income countries. Breast cancer five-year survival rates in high-income countries exceed 90%, compared with 66% in India and 40% in South Africa. Find out how to change this trend below.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.